FilingReader Intelligence
Zhejiang Medicine gets clinical trial approval for gastrointestinal drug
August 22, 2025 at 05:50 AM UTC•By FilingReader AI
Zhejiang Medicine received approval from the National Medical Products Administration for clinical trials of its XC2309 injection, a Class 1 chemical drug treating gastrointestinal bleeding.
The company invested 83.96m yuan in research and development for the XC2309 project. Similar drugs generated $936m globally and 825m yuan domestically in 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Zhejiang Medicine publishes news
Free account required • Unsubscribe anytime